213755-91-0

Basic information

• Product Name: 1-(3,4-DICHLOROPHENYL)CYCLOPENTANECARBONITRILE
• Synonyms: 1-(3,4-DICHLOROPHENYL)CYCLOPENTANECARBONITRILE;UKRORGSYN-BB BBV-5128503;CYCLOPENTANECARBONITRILE, 1-(3,4-DICHLOROPHENYL)-
• CAS NO: 213755-91-0
• Molecular Formula: C₁₂H₁₁Cl₂N
• Molecular Weight: 240.13
• Mol File: 213755-91-0.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-(3,4-DICHLOROPHENYL)CYCLOPENTANECARBONITRILE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(3,4-DICHLOROPHENYL)CYCLOPENTANECARBONITRILE(213755-91-0)
• EPA Substance Registry System: 1-(3,4-DICHLOROPHENYL)CYCLOPENTANECARBONITRILE(213755-91-0)

Safety Data

• Hazardous Substances Data: 213755-91-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-(3,4-DICHLOROPHENYL)CYCLOPENTANECARBONITRILE is used as an intermediate in the synthesis of various pharmaceuticals. Its unique structure allows for the development of new drugs with potential therapeutic benefits.
Used in Agrochemical Industry:
In the agrochemical sector, 1-(3,4-DICHLOROPHENYL)CYCLOPENTANECARBONITRILE serves as an intermediate for the production of different agrochemicals, contributing to the development of innovative solutions for agricultural challenges.
Used in Organic Chemistry:
As a versatile building block, 1-(3,4-DICHLOROPHENYL)CYCLOPENTANECARBONITRILE is used in the synthesis of a variety of organic compounds. Its structural features facilitate the creation of new molecules with potential applications in various industries.
Precaution:
1-(3,4-DICHLOROPHENYL)CYCLOPENTANECARBONITRILE should be handled and used with caution due to its potential health and environmental hazards. Proper safety measures and guidelines should be followed to minimize risks associated with its use.

Upstream product

• 110-52-1 1,4-dibromo-butane 
• 3218-49-3 3,4-dichloro-benzeneacetonitrile 

Downstream Products

• 213755-92-1 1-[1-(3,4-dichlorophenyl)cyclopentyl]ethan-1-one 
• 213755-93-2 2-bromo-1-[1-(3,4-dichlorophenyl)cyclopentyl]ethan-1-one 
• 944348-62-3 (1-(3,4-dichlorophenyl)cyclopentyl)methanamine 
• 437650-08-3 1-(3,4-dichloro-phenyl)-cyclopentanecarbonyl chloride 
• 437650-06-1 1-(3,4-dichlorophenyl)cyclopentanecarboxylic acid 

Relevant articles and documents

Cycloalkyl Amine Compounds

Cycloalkyl amine compounds of Formula (I), wherein ring A is C3-C6 cycloalkyl, optionally substituted with one or more C1-C3 alkyl, and R5 is ORS2, in which RS2 is H or C1-C6 alkyl, or R5 and R6, together with the carbon atom to which they are attached, form C═O, for use in treating CNS disorders, including movement disorders, depressive disorders, sleep disorders, cognitive dysfunctions, obesity, sexual dysfunction and substance abuse.

Discovery of N-methyl-1-(1-phenylcyclohexyl)methanamine, a novel triple serotonin, norepinephrine, and dopamine reuptake inhibitor

The current work discloses a novel cyclohexylarylamine chemotype with potent inhibition of the serotonin, norepinephrine, and dopamine transporters and potential for treatment of major depressive disorder. Optimized compounds 1 (SERT, NET, DAT, IC50 = 169, 85, 21 nM) and 42 (SERT, NET, DAT IC50 = 34, 295, 90 nM) were highly brain penetrant, active in vivo in the mouse tail suspension test at 30 mpk po and were not general motor stimulants.

PYRROLIDINE TRIPLE REUPTAKE INHIBITORS

In various embodiments, the present invention provides cycloalkyl pyrrolidine compounds and methods for their use in the treatment and/or prevention of various diseases, conditions and syndromes, including central nervous system (CNS) disorders, such as depression, anxiety, schizophrenia and sleep disorder as well as methods for their synthesis. The invention also relates to pharmaceutical compositions containing the compounds of the invention, as well as methods of inhibiting reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine from the synaptic cleft and methods of modulating one or more monoamine transporter.

Therapeutic agents

Compounds of formula I STR1 and pharmaceutically acceptable salts thereof in which m is 0, 1 or 2; n is 2, 3, 4 or 5; X is carbonyl or a group of formula II STR2 in which R5 is H or alkyl; Y is an alkylene chain optionally substituted by one or more alkyl groups; Z is an alkylene chain containing 2 to 5 carbon atoms optionally substituted by one or more alkyl groups; R is phenyl optionally substituted by one or more halo substituents or R is naphthyl; and R1 and R2, which are the same or different, are H, alkyl, or arylalkyl, provided that when R1 is benzyl, R2 is H or methyl; have utility in the treatment of depression, anxiety, Parkinson's disease, obesity, cognitive disorders, seizures, neurological disorders such as epilepsy, and as neuroprotective agents to protect against conditions such as stroke.